Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 2(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04610047Phase 2Completed

Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness

Role: lead

NCT04043923Phase 2Completed

Norketotifen for the Treatment of Uncomplicated Influenza-like Illness

Role: lead

NCT03887026Phase 2Completed

Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis

Role: lead

NCT03712163Phase 1Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Norketotifen in Healthy Subjects

Role: lead

All 4 trials loaded